Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy, compared with SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy.
Abstract
INTRODUCTION: Determining whether plasma biomarkers are preferentially associated with Alzheimer's disease (AD)-related rather than age-related brain atrophy patterns may clarify their prognostic and diagnostic clinical use.
Methods
Using data from the Baltimore Longitudinal Study of Aging (N=818), we examined cross-sectional plasma A{beta}42/A{beta}40, GFAP, NfL, p-tau181, and p-tau217 measurements obtained while participants were cognitively unimpaired (CU). During follow-up, 104 participants developed mild cognitive impairment (MCI)/dementia (74 due to AD, 24 due to non-AD, 6 unknown etiology). 2,293 longitudinal brain MRIs were used to quantify multidimensional atrophy pattern scores reflecting brain age (SPARE-BA), AD-like patterns (SPARE-AD), and five dominant dimensions of atrophy (R-indices). We investigated the associations of plasma biomarkers and atrophy pattern scores at index visit with conversion to MCI/dementia due to AD. We then examined the associations of plasma biomarkers with longitudinal change in pattern scores using linear mixed effects models.
Results
p-tau181, A{beta}42/A{beta}40 (Lumipulse), and p-tau217 were associated with incident MCI/dementia due to AD but not non-AD etiologies, while GFAP was associated with incident MCI/dementia due to both AD and non-AD. All four biomarkers were associated with longitudinal SPARE-AD changes. A{beta}42/A{beta}40 (Quanterix and Lumipulse), p-tau181, and p-tau217 were associated with longitudinal parieto-temporal atrophy. p-tau217 was the only biomarker associated with longitudinal medial temporal lobe atrophy. We did not find associations between plasma biomarkers and SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy.
Discussion
Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy.
BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk and supports its relevance for early risk stratification and prevention-oriented research.
E. Kuhn, G. Antopoulos, L. Kleineidam et al.· medRxiv· 0 citations
Abstract INTRODUCTION This study aimed to assess intra‐individual cognitive variability (IICV) in relation to Alzheimer's disease (AD) biomarkers. METHODS The National Alzheimer's Coordinating Center sample (n = 879), aged 50+ with a complete neuropsychological evaluation and AD biomarker data available (64% cognitivel...
S. S. Lin, Alicia L. Milam, Andrew Kiselica et al.· Alzheimer's & Dementia· 0 citations
Rare and common variants in AD- and neurodegenerative biomarker-associated genes with increased frequency in India compared to other populations may impact blood levels of neurodegenerative biomarkers in South Asians.
Hasan Abu-Amara, Wei Zhao, Zheng Li et al.· Frontiers in Aging Neuroscie...· 0 citations
Background Health-related factors may influence blood-based biomarkers (BBBM) of Alzheimer's disease (AD). In this analysis, associations between modifiable factors and plasma biomarkers of neurodegeneration were investigated across the Alzheimer's disease spectrum and in cognitively healthy controls in a cerebrospinal...
Carolin I. Kurz, Marleen Taute, Paulina Tegethoff et al.· Aging Brain· 0 citations
OBJECTIVE
To characterize spatiotemporal atrophy subtypes in biomarker-confirmed Alzheimer's disease (AD) and examine their cognitive, vascular, molecular, and longitudinal correlates.
METHODS
We applied Subtype and Stage Inference (SuStaIn) to baseline structural magnetic resonance imaging (MRI) from 484 amyloid-pos...
Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al.· NeuroImage· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.